Ocumetics Technology Corp. (TSXV:OTC)
Canada · Delayed Price · Currency is CAD | Market Cap | 59.18M -64.9% |
| Revenue (ttm) | n/a |
| Net Income | -7.57M |
| EPS | -0.06 |
| Shares Out | 142.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,767 |
| Open | 0.4200 |
| Previous Close | 0.4150 |
| Day's Range | 0.4200 - 0.4300 |
| 52-Week Range | 0.3500 - 1.3300 |
| Beta | 0.33 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 20, 2026 |
About Ocumetics Technology
Ocumetics Technology Corp. engages in research, development, production, and sale of vision enhancement products in Canada. It develops expandable intraocular lenses to eliminate the need for corrective lenses primarily for people over 45 years of age. The company was formerly known as Quantum Blockchain Technologies Ltd. and changed its name to Ocumetics Technology Corp. in August 2021. The company was founded in 2012 and is headquartered in Calgary, Canada. [Read more]
Financial Performance
Financial StatementsNews
Ocumetics Provides Summary of Group One Patient Clinical Progress
Key Highlights Ocumetics is developing an accommodating intraocular lens designed to provide a more natural range of vision, potentially addressing an important limitation of conventional intraocular ...
Ocumetics Announces Initiation of Patient Recruitment for Upcoming Group Two Human Clinical Surgeries
Key Highlights Group Two clinical study underway - Patient recruitment has begun in Mexico City, with surgeries targeted for Fall 2026 .
Ocumetics Completes Manufacturing of Next Generation Solid State Accommodating Intraocular Lenses for Upcoming Group Two First in Human Clinical Surgeries
Key Highlights Next-generation Ocumetics Lenses successfully manufactured and ready for the Company's upcoming Group Two first-in-human clinical surgeries in Mexico City.
Ocumetics Announces Completion of Third and Final Tranche of Unit Private Placement
Calgary, Alberta – TheNewswire - August 24, 2026 - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the third an...
Ocumetics Announces Completion of Second Tranche of Unit Private Placement
Calgary, Alberta – July 31, 2026 – TheNewswire - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the second tr...
Ocumetics Announces Upsizing of Unit Private Placement
Calgary, Alberta – TheNewswire - July 30, 2026. Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that as a result of strong investor ...
Ocumetics Announces Completion of First Tranche of Unit Private Placement
Calgary, Alberta – TheNewswire - July 29, 2026. Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the first tran...
Ocumetics Announces Corporate and Operational Update as Positive Six-Month Clinical Results Advance Next Phase of First-in-Human Study
Key Highlights Positive six-month results from the Company's First-in-Human ("FIH") study support advancement to Group Two clinical surgeries
Ocumetics Announces Offering of Units
Calgary, Alberta – TheNewswire - July 7, 2026 - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a privat...
Ocumetics Announces Significant Debt Conversion Strengthening Balance Sheet Ahead of Patient Study Milestones
Key Highlights $1.4 million of debenture principal converted to common shares of Ocumetics
Ocumetics Accelerates Toward Group Two First-In-Human Study with Manufacturing Launch of Optimized Accommodating Lens
Key Highlights Precision molds received for manufacturing of new optimized accommodating intraocular lenses
Ocumetics Reports Improvement in Six Month First-in-Human Results Meaningful Improvements in Patient Quality of Life
Key Highlights Vision performance: Clinical outcomes exceed expectations, with all patients experiencing continuing vision improvements
Ocumetics Technology Reports Attendance at ASCRS as Successful First-In-Human Trial Continues, No Material Change
Key Highlights No material change: There is no material change in the business affairs of Ocumetics.
Ocumetics to Showcase First-In-human Results with Industry Leaders & Potential Strategic Partners at ASCRS Annual Meeting
Key Highlights Early First-in-Human clinical results have drawn the attention of industry leaders and several of the largest vision care technology companies in the world.
Ocumetics Technology Corp. Achieves Breakthrough in Next-Generation Accommodating Intraocular Lens Design
Key Highlights Breakthrough Accommodating Interocular Lens Design: The enhanced lens design introduces several novel concepts that are expected to improve substantially upon the consistency, durabil...
Ocumetics Announces Issuance of Stock Options
Calgary, Alberta – March 13, 2026 – TheNewswire - Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) (the “ Corporation ”) announces that it has issued 500,000 incentive stock options ...
Ocumetics Announces Scientific Advisory Committee to Support Advancing Clinical and Regulatory Strategy
Calgary, Alberta – TheNewswire - February 26, 2026 - Ocumetics Technology Corp . (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technolog...
Ocumetics Announces Appointment of Raymond Marks to Board of Directors
Calgary, Alberta – TheNewswire - February 24, 2026 - Ocumetics Technology Corp . (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technolog...
Ocumetics Announces Forbearance Agreement for $4 Million Secured Convertible Debentures and Provides LIFE Offering Update
Calgary, Alberta – February 10, 2026 – TheNewswire - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is pleased to announce that the Corporatio...
Ocumetics Reports Positive Three Month First-in-Human Results, Significantly De-Risking Its Accommodating Intraocular Lens Technology
Key Highlights Positive First-in-Human Results: Three-month Group 1 data met or exceeded expectations for safety, lens delivery, and vision performance.
Ocumetics Announces Proposed Forbearance Agreement for $4 million Secured Convertible Debentures
Calgary, Alberta – January 30, 2026 – TheNewswire - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it is seeking approval from ...
Ocumetics Announces Transition of Chief Medical Officer Consulting Role
Calgary, Alberta – TheNewswire - January 9, 2026 - Ocumetics Technology Corp . (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology,...
Ocumetics Technology Announces Closing of First Tranche of Brokered LIFE Offering Led by Centurion One Capital
Calgary, AB – TheNewswire - January 2, 2026 – Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QB0) is pleased to announce that it has closed the fir...
Ocumetics Technology Announces Amendment to Brokered LIFE Offering Led by Centurion One Capital
Calgary, AB – TheNewswire - December 19, 2025 – Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QB0) announces that further to its previously announ...
Ocumetics Announces Optimized Lens Delivery System in Collaboration with Medicel
Calgary, Alberta – TheNewswire - December 9, 2025 - Ocumetics Technology Corp . (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology...